Metagenomics Market Expected to Reach $523 Million by 2024

According to a new report published by Allied Market Research, titled, Metagenomics Market by Product, Technology, and Application: Global Opportunity Analysis and Industry Forecast, 2018-2024, the global metagenomics market was valued at $176 million in 2017 and is expected to reach $523 million by 2024 at a CAGR of 16.8% during the forecast period. The bioinformatics segment accounted for one-fifth of the total market share in 2017.

Metagenomics is a relatively new field, which comprises the analysis of collective genomes of the members of the microbial community along with studying the interaction of microbes. In addition, metagenomic technologies enable the study of microbial communities as entire units without entailing the need of cultivating them. As non-cultivability and genomic diversity serve as the two major roadblocks in the advancements of environmental and clinical microbiology, metagenomics has gained immense traction among healthcare professionals and researchers.

In addition, rise in technological advancements regarding DNA sequencing is anticipated to drive the demand for metagenomic studies across the globe. Advancements in the same are highly focused towards the development of DNA sequencing platforms. Moreover, considerable expansion of metagenomic applications over the years has supplemented the market growth. The consumable segment generated the highest revenue in 2017 and is expected to maintain its dominance throughout the forecast period. This is attributed to the high adoption of consumables in pre-sequencing, which is one of the most important steps in the overall metagenomic sequencing protocol. This step comprises sample preparation, sample processing, and metagenomic sequencing.

The instrument & software segment is expected to register the highest growth rate during the forecast period. Several instruments and software are employed across metagenomic analysis, sequencing, sequence binning, annotation, taxonomic classification, statistical analysis, and data storage & sharing.

Based on application, the global metagenomics market is classified into infectious disease diagnosis, environmental remediation, gut microbe characterization, biotechnology, biofuel, and agriculture. The gut microbe characterization segment has dominated the global market in 2017 and is expected to maintain this dominance throughout the forecast period. Whereas, the infectious disease diagnosis segment has registered the fastest growth rate throughout the forecast period. The two common metagenomics methods used in the identification of infectious disease diagnosis include deep amplicon sequencing and whole-genome shotgun metagenomics.

Key Findings of the Metagenomics Market:

• The sequencing segment accounted for four-fifths of the total market share in 2017.
• The environmental remediation segment registered the second-highest growth rate among applications with a CAGR of 17.4% from 2018 to 2024.
• North America dominated the global metagenomics market, accounting for the maximum share in 2017, and is expected to retain the same trend during the forecast period.
• India has registered the highest growth rate in the Asia-Pacific metagenomics market with a CAGR of 19.7% during the forecast period.
• Germany accounted for two-sevenths of the total share in the European metagenomics market in 2017.

The Asia-Pacific region is expected to witness the highest growth rate throughout the forecast period, owing to its high population base, surge in disposable income, and rise in awareness towards new sequencing technologies. In addition, potential collaborations between the developed and developing economies working in the field of microbiome and metagenomics are the key contributors for the market growth in this region.

The major companies profiled in this report include Agilent Technologies, Inc., Enterome SA, F. Hoffmann-La Roche Ltd., Illumina, Inc., Oxford Nanopore Technologies Ltd., Pacific Biosciences of California, Inc., PerkinElmer, Inc., Qiagen N.V., Swift Biosciences, Inc., and Thermo Fisher Scientific, Inc. The other players operating in the global metagenomics market include Siemens AG, ZS Genetics, Inc., Abbott Laboratories, Beckman Coulter, LI-COR, Genomatix GmbH, Beijing Genomics Institute, and Pieriandx.